Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-453 | TNBC | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 9723.049 | 1.0393 | 1.0826 | 0.9525 | |
| MDA-MB-453 | TNBC | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 9723.049 | 1.0641 | 1.1349 | 0.9525 | |
| MDA-MB-453 | TNBC | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 9723.049 | 1.0157 | 1.0330 | 0.9525 | |
| MDA-MB-453 | TNBC | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 9723.049 | 1.0805 | 1.1693 | 0.9525 | |
| MDA-MB-453 | TNBC | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 9723.049 | 0.8743 | 0.7368 | 0.9525 | |
| MDA-MB-453 | TNBC | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 9723.049 | 0.4325 | -0.1705 | 0.9525 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7905.016 | 0.9593 | 0.8711 | 0.6240 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7905.016 | 0.9271 | 0.7715 | 0.6240 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7905.016 | 0.9231 | 0.7593 | 0.6240 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7905.016 | 1.1380 | 1.4605 | 0.6240 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7905.016 | 1.1984 | 1.6731 | 0.6240 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.267 | uM | 7905.016 | 1.2228 | 1.7608 | 0.6240 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 1.33 | uM | 7905.016 | 1.1856 | 1.6273 | 0.6240 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 6.67 | uM | 7905.016 | 1.1070 | 1.3538 | 0.6240 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 33.3 | uM | 7905.016 | 0.2428 | -0.7932 | 0.6240 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7906.016 | 1.1633 | 1.4148 | 0.8028 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7906.016 | 1.1499 | 1.3800 | 0.8028 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7906.016 | 0.7378 | 0.3694 | 0.8028 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7906.016 | 0.9703 | 0.9263 | 0.8028 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7906.016 | 0.9384 | 0.8477 | 0.8028 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.267 | uM | 7906.016 | 0.9040 | 0.7638 | 0.8028 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 1.33 | uM | 7906.016 | 0.7811 | 0.4702 | 0.8028 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 6.67 | uM | 7906.016 | 1.0562 | 1.1410 | 0.8028 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 33.3 | uM | 7906.016 | 0.6330 | 0.1315 | 0.8028 | |
| MDA-MB-468 | TNBC | Basal A | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7907.016 | 0.9711 | 0.9558 | 1.3145 |